Literature DB >> 17344346

Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease.

Steven D Lovrich1, Rhonda L La Fleur, Dean A Jobe, Jennifer C Johnson, Krista E Asp, Ronald F Schell, Steven M Callister.   

Abstract

Humans reliably produce high concentrations of borreliacidal OspC antibodies specific for the seven C-terminal amino acids shortly after infection with Borrelia burgdorferi. We show that dogs also produce OspC borreliacidal antibodies but that their frequencies, intensities, and antigenicities differ significantly. The findings therefore confirm a major difference between the borreliacidal antibody responses of humans and canines with Lyme disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344346      PMCID: PMC1865635          DOI: 10.1128/CVI.00431-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  17 in total

1.  Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant.

Authors:  Peter Kraiczy; Klaus-Peter Hunfeld; Stefan Peters; Reinhard Würzner; Georg Acker; Bettina Wilske; Volker Brade
Journal:  J Med Microbiol       Date:  2000-10       Impact factor: 2.472

2.  Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early lyme borreliosis from OspA vaccination.

Authors:  C A Wieneke; S D Lovrich; S M Callister; D A Jobe; J A Marks; R F Schell
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Authors:  Steven D Lovrich; Dean A Jobe; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

4.  Effects of bovine serum albumin on the ability of Barbour-Stoenner-Kelly medium to detect Borrelia burgdorferi.

Authors:  S M Callister; K L Case; W A Agger; R F Schell; R C Johnson; J L Ellingson
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

5.  Reassessment of a midwestern Lyme disease focus for Borrelia burgdorferi and the human granulocytic ehrlichiosis agent.

Authors:  Craig A Jackson; Steven D Lovrich; William A Agger; Steven M Callister
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Detection of borreliacidal antibodies in dogs after challenge with Borrelia burgdorferi-infected ixodes scapularis ticks.

Authors:  S M Callister; D A Jobe; R F Schell; S D Lovrich; K L Onheiber; J B Korshus
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 7.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  1989-08-31       Impact factor: 91.245

8.  C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Authors:  Dean A Jobe; Steven D Lovrich; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

9.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

10.  Complete heart block in a dog seropositive for Borrelia burgdorferi. Similarity to human Lyme carditis.

Authors:  S A Levy; P H Duray
Journal:  J Vet Intern Med       Date:  1988 Jul-Sep       Impact factor: 3.333

View more
  9 in total

Review 1.  Diversity of the Lyme Disease Spirochetes and its Influence on Immune Responses to Infection and Vaccination.

Authors:  Jerilyn R Izac; Richard T Marconi
Journal:  Vet Clin North Am Small Anim Pract       Date:  2019-04-06       Impact factor: 2.093

2.  Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses.

Authors:  Jerilyn R Izac; Andrew C Camire; Christopher G Earnhart; Monica E Embers; Rebecca A Funk; Edward B Breitschwerdt; Richard T Marconi
Journal:  Vaccine       Date:  2019-03-25       Impact factor: 3.641

3.  Humoral immune response in dogs naturally infected with Borrelia burgdorferi sensu lato and in dogs after immunization with a Borrelia vaccine.

Authors:  Michael W Leschnik; Georges Kirtz; Gelas Khanakah; Georg Duscher; Ernst Leidinger; Johann G Thalhammer; Anja Joachim; Gerold Stanek
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

4.  One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin.

Authors:  Rhonda L LaFleur; Steven M Callister; Jennifer C Dant; Dean A Jobe; Steven D Lovrich; Thomas F Warner; Terri L Wasmoen; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2010-03-17

5.  Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

Authors:  Rhonda L LaFleur; Jennifer C Dant; Terri L Wasmoen; Steven M Callister; Dean A Jobe; Steven D Lovrich; Thomas F Warner; O Abdelmagid; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

6.  Diversity of antibody responses to Borrelia burgdorferi in experimentally infected beagle dogs.

Authors:  Elisabeth Baum; Deborah A Grosenbaugh; Alan G Barbour
Journal:  Clin Vaccine Immunol       Date:  2014-04-02

7.  What maintains the high intra-follicular estradiol concentration in pre-ovulatory follicles?

Authors:  Yaakov Bentov; Andrea Jurisicova; Shlomit Kenigsberg; Robert F Casper
Journal:  J Assist Reprod Genet       Date:  2015-11-09       Impact factor: 3.412

8.  A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen.

Authors:  Sa Xiao; Manish Kumar; Xiuli Yang; Mustafa Akkoyunlu; Peter L Collins; Siba K Samal; Utpal Pal
Journal:  Vaccine       Date:  2011-05-19       Impact factor: 3.641

9.  Development and optimization of OspC chimeritope vaccinogens for Lyme disease.

Authors:  Jerilyn R Izac; Nathaniel S O'Bier; Lee D Oliver; Andrew C Camire; Christopher G Earnhart; DeLacy V LeBlanc Rhodes; Brandon F Young; Stuart R Parnham; Christopher Davies; Richard T Marconi
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.